个人中心 - 老虎社区

云吞面加咖喱

IP属地：未知

帖子 · 3帖子 · 3
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 云吞面加咖喱云吞面加咖喱
  ·2021-04-15
  Good
  Merck ends development of Covid drug it acquired from OncoImmune
  KEY POINTS Merck announced Thursday it will end the development of a Covid-19 drug it acquired from
  Merck ends development of Covid drug it acquired from OncoImmune
  964 评论
  点赞
  分享
  举报
- 云吞面加咖喱云吞面加咖喱
  ·2021-04-15
  Nice
  Opinion: VMware to finally come into its own in Dell spinoff, but strategic cloud remains
  After years of being majority-owned by another company,VMware Inc. finally will separate from its pa
  Opinion: VMware to finally come into its own in Dell spinoff, but strategic cloud remains
  688 评论
  点赞
  分享
  举报
- 云吞面加咖喱云吞面加咖喱
  ·2021-04-15
  Wow
  Merck ends development of Covid drug it acquired from OncoImmune
  KEY POINTS Merck announced Thursday it will end the development of a Covid-19 drug it acquired from
  Merck ends development of Covid drug it acquired from OncoImmune
  1,967 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575073750684504","uuid":"3575073750684504","gmtCreate":1611979727420,"gmtModify":1618540674540,"name":"云吞面加咖喱","pinyin":"ytmjklyuntunmianjiakali","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6d130edc8d13c6c564965a9a8d13dd60","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":5,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":347238063,"gmtCreate":1618496117652,"gmtModify":1634292528624,"author":{"id":"3575073750684504","authorId":"3575073750684504","name":"云吞面加咖喱","avatar":"https://static.tigerbbs.com/6d130edc8d13c6c564965a9a8d13dd60","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575073750684504","authorIdStr":"3575073750684504"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347238063","repostId":"1183968578","repostType":4,"repost":{"id":"1183968578","kind":"news","pubTimestamp":1618487325,"share":"https://www.laohu8.com/m/news/1183968578?lang=&edition=full","pubTime":"2021-04-15 19:48","market":"us","language":"en","title":"Merck ends development of Covid drug it acquired from OncoImmune","url":"https://stock-news.laohu8.com/highlight/detail?id=1183968578","media":"cnbc","summary":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from","content":"<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck ends development of Covid drug it acquired from OncoImmune</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck ends development of Covid drug it acquired from OncoImmune\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1183968578","content_text":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked for more data on the drug to support a potential emergency use authorization.\nDue to \"regulatory uncertainties\" and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug.\n\nMerckannounced Thursday it will end the development of its experimental drug for patients hospitalized with severe Covid-19 after the Food and Drug Administration asked the company to provide additional data to support an emergency use authorization.\nNew Jersey-based Merck acquired the drug, MK-7110, through its $425 million acquisition of privately held biopharmaceutical company OncoImmune late last year.\nAn interim analysis of clinical trial data suggested the drug improved the chances of recovery for the sickest patients with Covid-19 and reduced the risk of death or respiratory failure.\nHowever, Merck disclosed in February that U.S. regulators had asked for more data on the drug beyond the phase three trial already conducted. At the time, the company said it no longer expected to supply the U.S. with the drug in the first half of 2021.\nNow, due to “regulatory uncertainties” and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug and instead focus its efforts on advancing its other Covid-19 drug as well as accelerating production of the Johnson & Johnson vaccine.\n“Based on the additional research that would be required – new clinical trials as well as research related to manufacturing at scale – MK-7110 would not be expected to become available until the first half of 2022,” the company said in a press release.\nThe announcement marks another disappointment for Merck in efforts to combat the pandemic.\nIn January, it announced it wouldend the development of its two Covid-19 vaccines. In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from Covid-19 as well as those reported for other vaccines, according to the company.\nWhile Merck is discontinuing MK-7110, the company said it will move forward with its oral antiviral drug, molnupiravir, in a phase three clinical trial testing non-hospitalized patients with Covid-19.\n“We continue to make progress in the clinical development of our antiviral candidate molnupiravir,” Roy Baynes, Merck’s chief medical officer, said in a release. “Data from the dose-finding portion of these studies are consistent with the mechanism of action and provide meaningful evidence for the antiviral potential of the 800 mg dose.”","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":964,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347233787,"gmtCreate":1618496070749,"gmtModify":1634292529563,"author":{"id":"3575073750684504","authorId":"3575073750684504","name":"云吞面加咖喱","avatar":"https://static.tigerbbs.com/6d130edc8d13c6c564965a9a8d13dd60","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575073750684504","authorIdStr":"3575073750684504"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347233787","repostId":"1106526875","repostType":4,"repost":{"id":"1106526875","kind":"news","pubTimestamp":1618486948,"share":"https://www.laohu8.com/m/news/1106526875?lang=&edition=full","pubTime":"2021-04-15 19:42","market":"us","language":"en","title":"Opinion: VMware to finally come into its own in Dell spinoff, but strategic cloud remains","url":"https://stock-news.laohu8.com/highlight/detail?id=1106526875","media":"MarketWatch","summary":"After years of being majority-owned by another company,VMware Inc. finally will separate from its pa","content":"<p>After years of being majority-owned by another company,VMware Inc. finally will separate from its parent — now Dell Technologies. But the deal will not resolve the underlying issues for the virtualization software maker.</p>\n<p>Investors appeared to see it that way as well, sending shares of DellDELL,+0.18%up over 8% in after-hours trading Wednesday, while VMwareVMW,+0.71%tacked on less than 1%.</p>\n<p>“Compare how Dell’s stock is reacting and VMware shareholders watching the champagne party from afar,” said Dan Ives, an analyst at Wedbush Securities. “For VMware it removes an overhang, but it doesn’t change the fundamental strategic overhang that continues to plague the stock, and they are doing a spinoff at a time when their longtime leader has done an exit stage left to go to Intel.” (VMware CEOPat Gelsinger left to lead Intelearlier this year.)</p>\n<p>The “Rubik’s cube” of a deal, as Ives called the complicated transaction, has been a long time coming, and something investors have been seeking for nearly two years. Still, it won’t be complete until the end of this year, to ensure that the deal remains tax-free to Dell and its investors, who have the most to gain.</p>\n<p>The possibility of this ultimate spinoff first surfaced whenDell bought storage company EMC Corp. in a complex deal in 2016, which included EMC’s 81% stake in VMware, a developer of software that can act like the environment of another operating system on a network. Last year,the Wall Street Journal reported that Dell was actively considering its optionsfor the strategic stake, including a tax-free spinoff of VMware shares. Those options also included buying VMware outright or selling its 81% stake, which would have incurred a significant tax burden.</p>\n<p>Now, that is finally taking place, with Dell shareholders reaping the biggest rewards. All classes of Dell investors will receive 0.44 shares of VMware for each share of Dell that they own. VMware will pay Dell investors a hefty dividend of $11.5 billion to $12 billion, of which Dell, the company, will receive between $9.3 billion and $9.7 billion. That money will be used largely to pay off some of its outstanding debt.</p>\n<p>The estimated value of the $11.5 billion to $12 billion special cash dividend that VMware will provide to investors ranges from $27.43 per share to $28.62 per share, based on outstanding shares as of March 16, the company said.</p>\n<p>“We do believe that deleveraging in the next two years is important,” Zane Rowe, VMware’s chief financial officer and interim chief executive, said in a call with analysts. “We do believe we will get a lot more flexibility out of the balance sheet as well.”</p>\n<p>In order for the deal to close, Dell must receive a ruling from the Internal Revenue Service deeming the transaction tax-free.As previously reported, the spinoff will not be possible until September 2021, five years after Dell’s merger with EMC, to meet the tax requirements.</p>\n<p>The companies plan to continue their current business agreements, and collaborate and co-engineer products for customers. But the removal of this overhang from VMware’s stock does not take away its strategic issues. While VMware has been a strong player in the hybrid cloud arena, it is still dealing with the dueling revenue streams of its older, legacy licensing business, with subscription-based revenue for cloud-based customers.</p>\n<p>Without Dell’s ownership, VMware is now truly on its own for the first time in many years, but without a permanent CEO. Whoever eventually takes the helm needs to assure investors that they can make VMware stand out on its own.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opinion: VMware to finally come into its own in Dell spinoff, but strategic cloud remains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpinion: VMware to finally come into its own in Dell spinoff, but strategic cloud remains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/vmware-to-finally-come-into-its-own-in-dell-spinoff-but-strategic-cloud-remains-11618451068?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After years of being majority-owned by another company,VMware Inc. finally will separate from its parent — now Dell Technologies. But the deal will not resolve the underlying issues for the ...</p>\n\n<a href=\"https://www.marketwatch.com/story/vmware-to-finally-come-into-its-own-in-dell-spinoff-but-strategic-cloud-remains-11618451068?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DELL":"戴尔","VMW":"威睿"},"source_url":"https://www.marketwatch.com/story/vmware-to-finally-come-into-its-own-in-dell-spinoff-but-strategic-cloud-remains-11618451068?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1106526875","content_text":"After years of being majority-owned by another company,VMware Inc. finally will separate from its parent — now Dell Technologies. But the deal will not resolve the underlying issues for the virtualization software maker.\nInvestors appeared to see it that way as well, sending shares of DellDELL,+0.18%up over 8% in after-hours trading Wednesday, while VMwareVMW,+0.71%tacked on less than 1%.\n“Compare how Dell’s stock is reacting and VMware shareholders watching the champagne party from afar,” said Dan Ives, an analyst at Wedbush Securities. “For VMware it removes an overhang, but it doesn’t change the fundamental strategic overhang that continues to plague the stock, and they are doing a spinoff at a time when their longtime leader has done an exit stage left to go to Intel.” (VMware CEOPat Gelsinger left to lead Intelearlier this year.)\nThe “Rubik’s cube” of a deal, as Ives called the complicated transaction, has been a long time coming, and something investors have been seeking for nearly two years. Still, it won’t be complete until the end of this year, to ensure that the deal remains tax-free to Dell and its investors, who have the most to gain.\nThe possibility of this ultimate spinoff first surfaced whenDell bought storage company EMC Corp. in a complex deal in 2016, which included EMC’s 81% stake in VMware, a developer of software that can act like the environment of another operating system on a network. Last year,the Wall Street Journal reported that Dell was actively considering its optionsfor the strategic stake, including a tax-free spinoff of VMware shares. Those options also included buying VMware outright or selling its 81% stake, which would have incurred a significant tax burden.\nNow, that is finally taking place, with Dell shareholders reaping the biggest rewards. All classes of Dell investors will receive 0.44 shares of VMware for each share of Dell that they own. VMware will pay Dell investors a hefty dividend of $11.5 billion to $12 billion, of which Dell, the company, will receive between $9.3 billion and $9.7 billion. That money will be used largely to pay off some of its outstanding debt.\nThe estimated value of the $11.5 billion to $12 billion special cash dividend that VMware will provide to investors ranges from $27.43 per share to $28.62 per share, based on outstanding shares as of March 16, the company said.\n“We do believe that deleveraging in the next two years is important,” Zane Rowe, VMware’s chief financial officer and interim chief executive, said in a call with analysts. “We do believe we will get a lot more flexibility out of the balance sheet as well.”\nIn order for the deal to close, Dell must receive a ruling from the Internal Revenue Service deeming the transaction tax-free.As previously reported, the spinoff will not be possible until September 2021, five years after Dell’s merger with EMC, to meet the tax requirements.\nThe companies plan to continue their current business agreements, and collaborate and co-engineer products for customers. But the removal of this overhang from VMware’s stock does not take away its strategic issues. While VMware has been a strong player in the hybrid cloud arena, it is still dealing with the dueling revenue streams of its older, legacy licensing business, with subscription-based revenue for cloud-based customers.\nWithout Dell’s ownership, VMware is now truly on its own for the first time in many years, but without a permanent CEO. Whoever eventually takes the helm needs to assure investors that they can make VMware stand out on its own.","news_type":1,"symbols_score_info":{"DELL":0.9,"VMW":0.9}},"isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347233979,"gmtCreate":1618496042691,"gmtModify":1634292530290,"author":{"id":"3575073750684504","authorId":"3575073750684504","name":"云吞面加咖喱","avatar":"https://static.tigerbbs.com/6d130edc8d13c6c564965a9a8d13dd60","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575073750684504","authorIdStr":"3575073750684504"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347233979","repostId":"1183968578","repostType":4,"repost":{"id":"1183968578","kind":"news","pubTimestamp":1618487325,"share":"https://www.laohu8.com/m/news/1183968578?lang=&edition=full","pubTime":"2021-04-15 19:48","market":"us","language":"en","title":"Merck ends development of Covid drug it acquired from OncoImmune","url":"https://stock-news.laohu8.com/highlight/detail?id=1183968578","media":"cnbc","summary":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from","content":"<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck ends development of Covid drug it acquired from OncoImmune</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck ends development of Covid drug it acquired from OncoImmune\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1183968578","content_text":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked for more data on the drug to support a potential emergency use authorization.\nDue to \"regulatory uncertainties\" and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug.\n\nMerckannounced Thursday it will end the development of its experimental drug for patients hospitalized with severe Covid-19 after the Food and Drug Administration asked the company to provide additional data to support an emergency use authorization.\nNew Jersey-based Merck acquired the drug, MK-7110, through its $425 million acquisition of privately held biopharmaceutical company OncoImmune late last year.\nAn interim analysis of clinical trial data suggested the drug improved the chances of recovery for the sickest patients with Covid-19 and reduced the risk of death or respiratory failure.\nHowever, Merck disclosed in February that U.S. regulators had asked for more data on the drug beyond the phase three trial already conducted. At the time, the company said it no longer expected to supply the U.S. with the drug in the first half of 2021.\nNow, due to “regulatory uncertainties” and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug and instead focus its efforts on advancing its other Covid-19 drug as well as accelerating production of the Johnson & Johnson vaccine.\n“Based on the additional research that would be required – new clinical trials as well as research related to manufacturing at scale – MK-7110 would not be expected to become available until the first half of 2022,” the company said in a press release.\nThe announcement marks another disappointment for Merck in efforts to combat the pandemic.\nIn January, it announced it wouldend the development of its two Covid-19 vaccines. In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from Covid-19 as well as those reported for other vaccines, according to the company.\nWhile Merck is discontinuing MK-7110, the company said it will move forward with its oral antiviral drug, molnupiravir, in a phase three clinical trial testing non-hospitalized patients with Covid-19.\n“We continue to make progress in the clinical development of our antiviral candidate molnupiravir,” Roy Baynes, Merck’s chief medical officer, said in a release. “Data from the dose-finding portion of these studies are consistent with the mechanism of action and provide meaningful evidence for the antiviral potential of the 800 mg dose.”","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":1967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}